• PO Box 450 Mawson ACT, 2607 Australia

  • 02 6260 4022

Technical Alerts

Technical Alerts

This section contains Technical Alerts for members only - to access restricted Technical alerts member login is required.

  • 03 Nov 2022 4:23 PM | Anonymous member (Administrator)

    The TGA has published a web page and requested industry associations to remind affected medicine sponsors and manufacturers to be prepared that the Therapeutic Goods (Medicines Standard for Serialisation and Data Matrix Codes) (TGO 106) Order 2021 will commence on 1 January 2023 following the transition period provided

    This instrument does not mandate the use of data matrix codes or serialisation of medicines, but sets out mandatory requirements if medicine sponsors choose to do either of these things

    Medicines, including listed complementary medicines, released from supply from 1 January 2023 must comply with the requirements of TGO 106 if they:

     - are serialised (where each unit bears a unique identifier, allowing the unit to be identified distinctly within its batch); or

     - include a data matrix code that encodes a Global Trade Item Number (GTIN).

    For medicines that must comply with TGO 106, a data matrix code must be formatted as a GS1 DataMatrix, as set out in the GS1 General Specifications. TGO 106 also sets out specific requirements including:

     - how human readable information must be formatted on the primary pack; and

     - that information in a DataMatrix must be consistent with all machine-readable and human-readable information on the label, and any relevant content of the Product Information (PI) or Consumer Medicine Information (CMI).

    The guidance for TGO 106 clarifies the requirements of the standard, including readability and the need to include consistent GTINs if multiple machine-readable codes are present.

    Background: The TGA introduced TGO 106 in 2021 to provide clarity for adopters of serialisation and data matrix codes on medicines supplied in Australia. TGO 106 aligns with global standards to provide consistency for sponsors and manufacturers operating in multiple jurisdictions and to enable international interoperability. The TGO 106 and the associated guidance has been developed by the TGA with stakeholder input and feedback received during consultation.


     - Questions for TGA on the TGO 106 may be directed to  TGA.Scientific@health.gov.au

     - CMA may be contacted for industry issues at technical@cmaustralia.org.au

    Prior CMA tech alert:

     - CMA 29 march 2021 Tech alert: TGO 106 -New standard for medicines serialisation and data matrix code

  • 02 Nov 2022 12:24 PM | Anonymous member (Administrator)

    CMA have continued to seek clarification with the TGA on the status of titanium dioxide, in consideration of international changes that began with EFSA in 2021. The TGA have provided CMA with an update on their monitoring of domestic and international developments on the status of titanium dioxide, in response to these queries. Please note that this update is not on the TGA website.

    Please read todays full technical alert for more details, including additional information for member consideration from comparable national and international regulators.

  • 27 Oct 2022 12:12 PM | Anonymous member (Administrator)

    A public consultation on the interim decision for dichloromethane is now open, closing 24 November 2022.

    Dichloromethane (also known as methylene chloride) is a solvent for some materials used in complementary medicines, particularly lipid soluble fractions of plant extracts, and is therefore a residual solvent relevant to some CM finished products.

    In May 2022, the TGA consulted on a private applicant's proposal to change the Scheduling of dichloromethane from Schedule 5: Caution; to Schedule 10: Substances of such danger to health as to warrant prohibition of sale, supply and use, effectively prohibiting any use of dichloromethane. 

    After considering the submissions from 22 entities (17 opposed) including CMA, and advice from the Advisory Committee on Chemicals Scheduling (ACCS), a Delegate of the Secretary of the Department of Health and Aged Care has made an interim decision to not amend the current Poisons Standard in relation to dichloromethane. 

    While this is positive news, there are ongoing considerations for listed medicines that have not been resolved by the interim decision, which members may wish to consider in relation to making further submissions.

    Please read this technical alert for more details. 

  • 26 Oct 2022 3:22 PM | Anonymous member (Administrator)

    The TGA are seeking feedback, closing 5 December 2022, on proposed changed to Safety Reporting Requirements as described in the Pharmacovigilance responsibilities of medicine sponsors: Australian recommendations and requirements guidance document (the PV guidelines). 

    Please ensure your officers responsible for Pharmacovigilance receive this technical alert

    The intention of the proposed changes is stated to increase the quality of notifications, enabling the TGA to act on all safety issues in a timeframe proportionate to the risk to public health. The TGA also state that the aim is not to lessen the current requirements for reporting of safety issues, but to better define which issues are to be notified urgently by sponsors, supporting timely responses to new safety information by the TGA.

    This technical alert provides information for members on key aspects of the proposed changes to the PV Guidelines, including related documents and resources. 

  • 18 Oct 2022 3:38 PM | Anonymous member (Administrator)

    The TGA will be conducting targeted compliance reviews of selected listed medicines that contain colecalciferol (Vitamin D) and bone related indications, beginning Oct/Nov 2022. The review does not  include review of products that contain vitamin D and calcium.

    This technical alert provides more information for sponsors, including additional contextual information on studies that may have informed the review, and comparable international perspectives. 

  • 18 Oct 2022 7:39 AM | Anonymous member (Administrator)

    The TGA's Pharmacovigilance Inspection Program (PVIP) Risk Assessment Survey, open until 18 December 2022, is designed to inform the TGA about a sponsors medicine portfolio, pharmacovigilance system, inspection history and compliance with Australian pharmacovigilance legislation and guidelines, and will serve as a tool to help prioritise and schedule pharmacovigilance inspections of sponsors.

    Please note: Any sponsors who has at least one medicine included on the Australian Register of Therapeutic Goods (ARTG) should complete this survey. medicine sponsors that do not complete this survey will be assigned the highest survey risk score, meaning you will have a very high chance of receiving a Pharmacovigilance Inspection under the TGA's PVIP.

    The survey questions relate only to medicines (not medical devices or biologicals) in the ARTG including all listed, registered and provisionally registered medicines.

    Sponsors are directed to complete and submit their survey responses online; the survey consists of 24 questions and must be completed in one attempt only. Partially completed surveys will not be recorded and cannot be retrieved for later use.

    The TGA request that stakeholders answer the questions carefully and truthfully as they may ask for evidence of responses during a pharmacovigilance inspection. A copy of the survey questions is available to assist stakeholders prepare their responses prior to submission.

  • 11 Oct 2022 3:57 PM | Anonymous member (Administrator)

    The TGA is seeking feedback, via online survey closing 20 November 2022, on the draft guidance ‘Boundary and combination products - medicines, medical devices, and biologicals’. 

    The existing guidance is out of date and requires updating to reflect significant changes in the regulation of therapeutic goods since 2005. The purpose of the draft guidance is to assist sponsors and manufacturers in determining the status of therapeutic goods that may not fit clearly within existing definitions for medicines, biologicals, or medical devices, providing clarity on which regulatory pathway is appropriate for therapeutic goods which are considered Boundary and combination products.

    The draft guidance also reflects the recent changes to Class 1 medical devices, as part of the ongoing medical device reforms, and raises other areas relevant to listed and complementary medicines such as head lice, lozenges and nail fungus products.  

    Please read today’s full tech alert for more information, including a comparison of the 2005 guidance and the draft guidance, and details on how to respond to the consultation.

  • 10 Oct 2022 3:33 PM | Anonymous member (Administrator)

    Today's technical alert provides information on the Therapeutic Goods Advertsising Annual Report 2021-22; and the TGA update to the approach to overseas manufacturers during the OCVID-19 Pandemic: GMP Clearance MRA pathway.

    Therapeutic Goods Advertising Annual Report 2021-22

    The annual outcomes of the TGA’s 2021-22 advertising compliance and enforcement activities have been published in the Therapeutic Goods Advertising Annual Report 2021-22 on the TGA website. This tech alert provides contextually relevant information for members, including in relation to listed and complementary medicines. 

    TGA update to the GMP approach to overseas manufacturers during the COVID-19 Pandemic: GMP Clearance Pathway 

    The TGA have provided an update their GMP approach to overseas manufacturers during the COVID-19 Pandemic, which outlines additional options for Australian Sponsors to maintain their GMP Clearance validity and provides additional application guidance.

    Please read today’s full tech alert for more information.

  • 04 Oct 2022 1:02 PM | Anonymous member (Administrator)

    Registration is now open for a USP live webcast on nitrosamine impurities, to be held on 13 October 2022. More information and details on how to register are available via this USP web page

    CMA’s 27 July technical alert provides more background and context for members.

    Course Description:

    This one-day course will provide attendees with an understanding of current regulatory guidelines and USP General Chapter <1469> Nitrosamine Impurities. The course will provide an overview of sources of nitrosamines including their formation from the presence of other impurities and how to eliminate or reduce levels of nitrosamines. Tools to assess and control nitrosamines in drug substances and drug products as well as in depth analytical procedures in USP <1469> including the use of the USP Reference Standard and precautions to be used during procedures will also be covered. The course will also address risk assessment methodology as per ICH9, control strategy development, calculation of nitrosamine limits as per ICH M7 as well as test method performance characteristics.

    Upon completion of this course, attendees will be able to

     - Describe the background, scope and approach of USP <1469> Nitrosamine Impurities and applicable regulatory guidelines.

     - Explain pathways and sources of nitrosamine formation along with risk assessment tools and a high- level process flow to develop control strategies.

     - Describe how to select the appropriate analytical procedures based on test method performance characteristics for nitrosamine methods

     - Discuss the proper use and handling of the USP reference standard in the respective analytical procedures.

     - Identify factors which impact sensitivity and selectivity of methods

     - Summarize key considerations, challenges and method conditions along with sample and standard preparation of the four test methods described in USP <1469>

    Who should participate:

     - R&D manufacturers

     - QC managers

     - QC staff scientists (DS, DP)

     - Excipient manufacturers

     - Research scientists

     - QA staff who authorize drug product release

  • 28 Sep 2022 2:22 PM | Anonymous member (Administrator)

    Two TGA consultations have recently been announced:

    Regulatory options to potentially allow references to the TGA in therapeutic goods advertising

    This Public Consultation, closing 7 November 2022, considers potential options on whether allowing references to the TGA in therapeutic goods advertising (and on product labels) may support consumers to make better informed health decisions by more clearly identifying products that have met the regulatory requirements and are being lawfully advertised and sold.

    The TGA are seeking feedback on:

    - whether references to the TGA should be allowed in therapeutic goods advertising the class or classes of therapeutic goods, if any, that should be allowed to refer to the TGA;

    - options for what a reference to the TGA could look like;

    - options for how an authorised reference to TGA may be used in advertising; and

    - whether references to TGA should be optional or mandatory for advertisers.

    DAEN user experience survey

    This online survey, closing 26 October 2022, is seeking feedback on stakeholder experience of the beta version of the database of adverse events notifications (DAEN), providing the opportunity for stakeholders to identify any areas of the beta version that are problematic or not fit for purpose prior to implementation.

    Please read today’s full technical alert for more information and details.

Copyright © 2019 Complementary Medicines Australia. All rights reserved.

Powered by Wild Apricot Membership Software